Key result
Xuezhitong lowers triglycerides by ~31% vs. placebo in patients with hypertriglyceridemia.
Why the study?
Xuezhitong is an extract with lipid-lowering properties, but its effects on lipids in subjects with hypertriglyceridemia without severe dyslipidaemia needed evaluation.
Does Xuezhitong reduce triglyceride levels in subjects with hypertriglyceridemia without severe dyslipidemia?
RCT (n=358)
Double-blind
Centrally designed randomisation code
Yes
Does Xuezhitong reduce triglyceride levels in subjects with hypertriglyceridemia without severe dyslipidemia?
Xuezhitong (2700 mg daily) significantly reduces triglyceride levels and improves other lipid parameters over 12 weeks in patients with hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
XZT safely lowers TG more than placebo in HTG; extends RCT evidence for Allium extracts as lipid-lowering options.
BACKGROUD: Xuezhitong (XZT) is an extract of Allium macrostemon Bunge that has lipid-lowering properties. OBJECTIVE: To evaluate the effects of XZT on lipids in subjects with hypertriglyceridemia (HTG) without severe dyslipidaemia. METHODS: A total of 358 subjects with HTG were enrolled and randomly assigned to receive XZT (2700 mg daily), xuezhikang (XZK) (1200 mg daily) or placebo. The primary endpoint was the reduction or percent reduction in the TG level over 12 weeks of treatment. RESULTS: At the 12-week follow-up, a reduction in the TG level from baseline was observed in both groups, but the XZT and XZK groups demonstrated a significantly greater reduction than the placebo group (30.77%, 24.02% vs 11.59%, P < 0.0167); 70.54% of subjects in the XZT group and 62.30% of subjects in the XZK group demonstrated reductions in TG levels of at least 20%, compared with 41.67% of the subjects in the placebo group (P < 0.0167). Treatment with XZT capsules also demonstrated superior performance compared with the placebo with respect to the control of lipids (17.97% vs 5.00%), total cholesterol (TC) (14.18% vs 3.89%), low-density lipoprotein cholesterol (LDL-C) (17.98% vs 2.95%), and high-density lipoprotein cholesterol (HDL-C) (21.47% vs 2.16%). Daily use of XZT for 12 weeks resulted in statistically significant (65.22% vs 38.30%, 25.00%; P < 0.0167) and clinically meaningful increases in HDL-C levels by ≥4 mg/dl compared with XZK and placebo. XZT was safe and well tolerated; the safety and tolerability profiles were similar across treatment groups. No subject experienced myopathy or markedly elevated liver transaminases or creatine kinase. CONCLUSIONS: XZT significantly reduced TG levels and was well tolerated. Longer-term studies in more diverse patient populations are needed to corroborate these findings. CLINICAL TRIAL REGISTRATION: www.chictr.org.cn Identifier: ChiCTR1900025854.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2020) conducted an RCT in Hypertriglyceridemia (n=358). Xuezhitong vs. Xuezhikang (1200 mg daily) or placebo was evaluated on Percent reduction in triglyceride (TG) level from baseline to 12 weeks (p=<0.0167). Xuezhitong significantly reduced triglyceride levels by 30.77% from baseline compared to an 11.59% reduction with placebo over 12 weeks in patients with hypertriglyceridemia.
Synapse has enriched 10 related papers. Consider them for comparative context: